hrp0089rfc4.5 | GH & IGFs | ESPE2018
Malievskiy Oleg
, Mykola Aryaev
, Nataliya Zelinska
, Bolshova Elena V
, Senatorova Ganna
, Oroszlan Gyorgy
, Skorodok Julia
, Peterkova Valentina
, Nataliya Chorna
, Sorokman Tamila
, Yang Seung
, Lee Ji Eun
, Muzsnai Agota
, Hwang Jin Soon
, Lee Sang Yoon
, Choi Yun Jung
, Ji Hyi-Jeong
, Woo Jungwon
, Sung Young-Chul
GX-H9 is a long-acting form of recombinant human GH under clinical development for both adults and children with GH deficiency (GHD). This study was designed to compare 12-month effects of once-weekly and twice-monthly (every other week; EOW) administration of GX-H9 treatment to that of Genotropin®, in pediatric patients with GHD. A randomized, open-label, active-controlled, parallel study was conducted at 27 endocrinology centers in 10 countries (Europe and Ko...